✦ LIBER ✦

Paclitaxel cytotoxicity is significantly enhanced by a novel pro-apoptotic agent in the treatment of non-small cell lung cancer

✍ Scribed by Syed Shahzad Razi; Koji Park; Xiaogui Li; George Jour; Gary Schwartz; George Todd; Scott Belsley; Cliff P. Connery; Faiz Y. Bhora

Book ID: 113680612
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 98 KB
Volume: 213
Category: Article
ISSN: 1072-7515
DOI: 10.1016/j.jamcollsurg.2011.06.085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-Tumor Activity Of Cisplatin And Pac

Anti-Tumor Activity Of Cisplatin And Paclitaxel Is Significantly Enhanced By A Novel Pro-Apoptotic Agent In Non-Small Cell Lung Cancer

✍ S.S. Razi; X. Li; K. Park; G. Schwartz; S. Belsley; C.P. Connery; F.Y. Bhora 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Is cisplatin necessary for the treatment

Is cisplatin necessary for the treatment of non-small cell lung cancer (NSCLC)? — Analysis of consecutive trials of paclitaxel in NSCLC

✍ Kubota, K; Nishiwaki, Y; Yokoyama, A; Yoneda, S; Tamura, T; Watanabe, K; Saijo, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 101 KB

439 POSTER The cytotoxic activity of the

439 POSTER The cytotoxic activity of the telomere binding agent KML001 in non-small cell lung cancer cells is dependent on telomere length and p53 status and is enhanced by cisplatin

✍ P. Phatak; M. Edelman; H. Hendriks; A. Burger 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

PCNI8 A COST COMPARISON OF GEMZAR PLUS C

PCNI8 A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY

✍ A Kielhorn; G Stynes; S Bhalla; D Tilden 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Enhanced cytotoxicity induced by gefitin

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells

✍ Maarten L. Janmaat; José A. Rodriguez; Mariëlle Gallegos-Ruiz; Frank A.E. Kruyt; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 371 KB

## Abstract In this study, we have characterized a panel of NSCLC cell lines with differential sensitivity to gefitinib for activating mutations in __egfr__, __pik3ca__, and __k‐ras__, and basal protein expression levels of PTEN. The __egfr__ mutant NSCLC cell line H1650 as well as the __egfr__ wil

Paclitaxel plus cisplatin is as effectiv

Paclitaxel plus cisplatin is as effective as regimens containing gemcitabine in people with advanced non-small cell lung cancer: Abstracted from: Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909–17.

✍ Sarah Danson 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 163 KB